Undisclosed EGFRC797S inhibitor / Schrodinger - LARVOL DELTA

Schrödinger Reports First Quarter 2024 Financial Results (Businesswire) - "Today, Schrödinger also announced that the U.S. Food and Drug Administration (FDA) cleared the investigational new drug (IND) application for SGR-3515, its Wee1/Myt1 inhibitor. Schrödinger expects to initiate a Phase 1 dose-escalation trial of SGR-3515 in patients with solid tumors in the third quarter of 2024....Schrödinger is progressing its discovery pipeline, including programs targeting EGFRC797S, PRMT5-MTA and NLRP3. The company continues to anticipate submitting at least one IND in 2025."

IND • New P1 trial • Solid Tumor